In a bid to retrieve tens of millions of dollars over the next several years, New York University has filed a lawsuit against Pfizer, claiming the drugmaker failed to pay royalties on its Xalkori medication, which was approved two years ago by the FDA to treat non-small cell lung cancer along with a diagnostic kit. The dispute is the latest example of a spat over the proceeds from research that is generated by academia but is commercialized by a drugmaker under a development deal. In this instance, NYU claims that Pfizer did not honor an agreement that was inherited as part of its 2003 acquisition of Pharmacia.